View Cart  

Bill Provides Temporary Band-Aid for Exclusivity Forfeiture Clause

A A
As the FDA’s backlog of ANDAs continues to grow, it’s become increasingly common for generic-drug makers to lose their 180-day exclusivity by not gaining timely tentative approval.

To View This Article:

Login

Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00